Practical stacking considerations Researchers interested in replicating a CagriSema-like protocol need to manage two separate peptides with their own reconstitution, storage, and dosing requirements
Adding amylin agonism to a dual or triple incretin agonist is mechanistically plausible, but the concern is stacked gastrointestinal burden: adding semaglutide alone pushed GI events from 54.0% to 79.6%, and discontinuations from 2.6% to 5.9%
For the peptides under consideration, the small size of the copper tripeptide (3 amino acids), the thymosin fragment (7 amino acids), and the body protection compound (15 amino acids) likely limits benzyl alcohol interactions compared to larger proteins
Most GI symptoms are temporary and peak during dose escalations
The AAFP advises that injectable therapy leads to more rapid improvement and should be considered in patients with severe deficiency or severe neurologic symptoms (Langan RC, Goodbred AJ, 2017)